Background: Ivermectin has been a popular anti-parasitic drug since the late 1970s. The promising result of in-vitro studies on the antiviral activity of the drug has led clinicians in many countries to use this drug to treat COVID-19 patients. This study determined and compared the mean number of days at clinical recovery for mild to moderate cases of COVID -19 treated with Lopinavir/Ritonavir (Alluvia) and Ivermectin at the Kaduna State Infectious Disease Control Centres.
Methods: This was a comparative cross-sectional study conducted among 300 mild to moderate COVID- 19 cases enrolled for the study. The outcome variables were the time required for the resolution of symptoms from the onset and at commencement of the treatment regimens. Data were collected from patient folders using a questionnaire. Data were analysed with the IBM SPSS Version 25.0 and STATA/SE 13. Statistical significance was set at p<0.05.
Results: The mean recovery time (MRT) from symptom onset was significantly lower for Covid-19 patients treated with ivermectin (7.15±4.18 days) compared to lopinavir/ritonavir (9.7±5.3 days), 95%CI=7.37-9.62. Multivariate logistic regression showed that there was no significant relationship between the patients age (AOR=0.36, 95%CI=0.09-1.49), sex (AOR=0.34,95%CI=0.54-5.93), educational status (AOR=1.04, 95%CI=0.3-3.57), marital status (AOR=0.55,95%CI=0.14-2.11) place of treatment (AOR=1.66, 95%CI=0.54-5.11) and MRT. There was also no significant relationship between patients' comorbid chronic illness (AOR=0.83, 95%CI=0.27-2.61) and MRT.
Conclusion: The mean recovery time for COVID-19 patients managed with ivermectin was slightly lower than for the lopinavir/ ritonavir regimen.
Recommendation: Clinical trials to further prove the efficacy of Ivermectin as a supportive therapy in clinical management of mild to moderate cases of COVID-19 in this setting should be carried out.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Novel brain SPECT imaging unravels abnormal cerebral perfusion in patients with postural orthostatic tachycardia syndrome and cognitive dysfunction.
Sci Rep
January 2025
Australian Dysautonomia and Arrhythmia Research Collaborative, Adelaide, SA, Australia.
Cognitive dysfunction is frequently reported in individuals with postural orthostatic tachycardia syndrome (POTS), possibly resulting from reduced cerebral blood flow (CBF). We used brain SPECT, an accessible imaging modality that has not been systematically evaluated in this patient group. Retrospective review of participants from our registry was undertaken to identify those who had a brain SPECT performed for investigation of cognitive dysfunction.
View Article and Find Full Text PDFSafety and Immunogenicity of Omicron Protein Vaccines in mRNA-Vaccinated Adolescents: A Phase 3, Randomised Trial.
J Infect
January 2025
Research Your Health, 6020 West Parker Road, Suite 430, Plano, Texas, 75093, USA.
Objectives: Safety and immunogenicity assessment of updated monovalent and bivalent SARS-CoV-2 vaccines in adolescents.
Methods: This phase 3, double-blinded study randomised 12-<18-year-old participants, who received ≥2 prior doses of an approved/authorised mRNA-based COVID-19 vaccine, 1:1 to receive NVX-CoV2601 (XBB.1.
Assessment of a semiquantitative scoring system for mild-to-moderate gill lesions in Atlantic salmon reared in recirculating aquaculture systems in Norway.
J Vet Diagn Invest
January 2025
Åkerblå, Sistranda, Norway.
Compromised gill health is a critical cause of forfeited welfare in Atlantic salmon farming. Detecting and quantifying the early onset of gill disease is important to reveal initial inflicting stimuli. We collected gill samples of 45 Atlantic salmon from 2 commercial recirculating aquaculture systems (RASs) spanning fry-to-market-size fish with no clinical signs of gill disease.
View Article and Find Full Text PDFDepressive, anxiety, and sleep disturbance symptoms in patients with obstructive sleep apnea: a network analysis perspective.
BMC Psychiatry
January 2025
Department of Psychiatry Sleep Medical Center, Nanfang Hospital Southern Medical University, No. 1838 North Guangzhou Avenue, Guangzhou, 510515, China.
Background: Patients with obstructive sleep apnea (OSA) frequently experience sleep disturbance and psychological distress, such as depression and anxiety, which may have a negative impact on their health status and functional abilities. To gain a more comprehensive understanding of the symptoms of depression, anxiety, and sleep disturbance in patients with OSA, the current study utilized network analysis to examine the interconnections among these symptoms.
Methods: Depressive and anxiety symptoms were evaluated using the Hospital Anxiety and Depression Scale (HADS), and sleep disturbance symptoms were evaluated using the Pittsburgh Sleep Quality Index (PSQI).
Illnesses and Diseases Constitute a Quarter of Medical Conditions in an Under-21 National Football Team.
J Sport Rehabil
January 2025
Department of Hand Surgery, Bridge Hospital, Helsinki University Central Hospital and University of Helsinki, Helsinki, Finland.
Context: There is a minimal number of studies of under-21-year-old national football teams, and the literature is injury centric. Particularly, current knowledge is deficient regarding noninjurious medical conditions, such as illnesses and diseases.
Design: The objectives of this study were to analyze the descriptive characteristics of injuries and illnesses or diseases encountered in an under-21 football team during 2 European championship qualification tournaments.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!